Tag: Statistically

Teva's Reslizumab Delivers Clinically and Statistically Significant Reduction …Wall Street JournalTeva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma … View full post on asthma – Google News